期刊文献+

星形细胞上调基因-1在原发性肝细胞癌组织中的表达及意义

Expression and significance of astrocyte elevated gene-1 gene in primary hepatocellular carcinoma
原文传递
导出
摘要 目的探讨星形细胞上调基因-1(astrocyte elevated gene-1,AEG-1)在原发性肝细胞癌组织中的表达及其意义。方法 60例肝细胞癌患者,取其肝癌组织60份为肝癌组,癌旁肝组织54份为对照组,采用荧光定量PCR法检测2组AEG-1mRNA表达情况,采用Western blot法检测AEG-1蛋白表达情况,采用免疫组织化学法检测AEG-1阳性表达率,分析AEG-1蛋白表达与病理指标间的关系。结果肝癌组AEG-1mRNA和蛋白相对表达量(4.71±2.87、1.27±0.62)及AEG-1阳性表达率(53.3%)均明显高于对照组(1.43±0.49、0.69±0.25、29.6%)(P<0.05);肝癌组织AEG-1阳性表达水平在肿瘤转移及病理分级上差异无统计学意义(P>0.05)。结论 AEG-1在原发性肝细胞癌组织中特异性表达增高,可能是诊断原发性肝细胞癌的生物学标记物。 Objective To investigate the expression of astrocyte elevated gene-1 (AEG-1) in primary hepatocellular carcinoma (HCC) and its clinical significance. Methods The expression of AEC-1 mRNA was detected by fluorescence quantitative PCR technique, AEG-1 protein was detected by Western blot method, and the positive rate of AEG-I was detected by immunohistochemical method in 60 samples of HCC tissue (HCC group) and 54 samples of adjacent tissue (control group) from 60 patients with HCC. The relationship between the expression of AEG-1 gene and pathological index was analyzed. Results The relative expressions of AEG-1 mRNA and protein and the positive expression rate of AEG-1 protein were significantly higher in HCC group (4.71±2.87, 1.27±0.62, 53.3%) than those in control group (1.43±0.49, 0.69±0.25, 29.6%) (P〈0.05). There was no significant difference in the positive expression level of AEG -1 in tumor metastases and pathological grading in HCC group (P〉0.05). Conclusion AEG 1 is highly expressed in primary HCC tissue, suggesting that AEG-1 may be regarded as a biomarker for the diagnosis of primary HCC.
出处 《中华实用诊断与治疗杂志》 2016年第8期754-756,共3页 Journal of Chinese Practical Diagnosis and Therapy
基金 江西省自然科学基金(20142BBG70117)
关键词 原发性肝细胞癌 星形细胞上调基因-1 生物学标志物 Primary hepatocellular carcinoma astrocyte elevated gene-1 biomarker
  • 相关文献

参考文献13

  • 1Emdad L, Lee SG, Su ZZ, et al. Astrocyte elevated gene--1 (AEG-1) functions as an oneogene and regulates angiogenesis [J]. Proc Natl Acad Sci USA,2009,106(50):21300-21305.
  • 2Yoo BK, Emdad L, Su ZZ, et al. Astroeyte elevated gene 1 regulates hepatocellular carcinoma development and progression [J]. J Clinlnvest,2009,19(3):465-477.
  • 3Srivastava J, Robertson CL, Gredler R, et al. Astrocyte elevated gene 1 (AEG 1) contributes to non- syndrome (NTIS) associated with hepatocel (HCC)[J]. J Biol Chem,2015,290(25):15549- hyroi ular 5558 I,iu.
  • 4B, Wu Y, Peng D. Astrocyte elevated gene 1 regulates osteosarcoma cell invasion and chemoresistance via endothelin-1/ endothdin A receptor signating[J]. Oncol .ett, 20 l 3,5 (2) : 505- 510.
  • 5雷长江,李磊,龙浩成,王斌,曾诚,黄剑彬.Yes相关蛋白在人肝细胞肝癌中表达及意义[J].中华实用诊断与治疗杂志,2015,29(3):244-246. 被引量:4
  • 6Song L, Li W, Zhang H, et al. Over-expression of AE significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer[J]. J Pathol, 2009,219(3) :317-326.
  • 7Zhu K, Dai Z, Pan Q, et al. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial mesenchymal transition[J]. Clin Cancer Res, 2011 17(23):7294-7302.
  • 8Gong Z, Liu W, You N, et al. Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma[J]. Oncol Rep, 2012, 27 (6): 20732079.
  • 9季辉华,李云飞,张少峰.原发性肝细胞癌膀胱远处转移1例报告并文献复习[J].中华全科医学,2011,9(10):1659-1660. 被引量:3
  • 10应希慧,纪建松,涂建飞,张登科.原发性肝癌合并骨转移45例临床分析[J].中华全科医学,2014,12(8):1346-1347. 被引量:7

二级参考文献43

  • 1Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sor- afenib in patients in the Asia - Pacific region with advanced hep- atocellular carcinoma:a phase III randomized, double - blind, placebo - controlled trial [ J ]. Lancet Oncol, 2009,10 ( 1 ) :25-34.
  • 2Flaherty KT. Sorafenib:delivering a targeted drug to the right tar- gets. Expert Rev Anticaneer Ther,2007,7 (5) :617-626.
  • 3Hampton T. Cancer drug trims show modest benefit: drugs taget liver, gastric, head and neck caners. JAMA, 2007,298 ( 3 ) : 273- 275.
  • 4Liu L, Ca Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ ERK pathway,inhibits tumor angIogenesis, and induces tumor cell apoptcsis in hepatocellular carcinoma mode[ PLC/PRW/5. Canc- er Res ,2006,66 (24) : 11851-11858.
  • 5Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008,359 ( 4 ) : 378- 390.
  • 6Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008,48 ( 4 ) : 1312 -1327.
  • 7Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) ,2005,41 ( 12 ) :773-784.
  • 8Jemal A, Bray F, Center MM, et al. Global Cancer statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69-90.
  • 9Ferlay J, Shin HR, Bray F, eta|. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 [ J 1. Int J cancer,2010,127 (12) : 2893-2897.
  • 10Luxon BA. Bone disorders in chronic liver diseases [ J ]. Curr Gastroen- terol Rep,2011,12( 1 ) :40-48.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部